SoSoThin.com launched a cash-pay semaglutide weight loss service on February 16, 2026. The company said the model offers fast access, transparent pricing, and a digital-first process without insurance delays.
GLP-1 drugs are expanding in 2026 with oral semaglutide for weight management, rising patient use and broader commercialization. A study also found a modest increase in erectile dysfunction risk among men with Type 2 diabetes starting GLP-1 medicines, though the association weakened after stricter adjustment.
Q1 2026 sleep medicine trends include broader use of AI, expanding obstructive sleep apnea and narcolepsy treatments, and policy changes affecting reimbursement and access.
The TrumpRx prescription discount website launched in February 2026 offers coupons for 43 brand-name drugs but has limited usefulness for most patients. Experts found 18 drugs are cheaper through other discount services, and the website doesn't indicate when generic alternatives exist. The program links to broader tariff and pricing policies affecting pharmaceutical companies.
Kodiak Sciences' experimental drug Zenkuda achieved 62.5% response rate in diabetic retinopathy trial with 85% reduction in sight-threatening complications. The company plans to accelerate FDA submission while preparing for wet AMD study readout in Q3 2026. Shares surged 68.6% following the positive late-stage results.
The FDA is set to make decisions on four drug applications in April 2026, including Orca-T for hematological malignancies, orforglipron for obesity, sparsentan for kidney disease, and a doravirine/islatravir combination for HIV-1.
Bunnie Xo, wife of country star Jelly Roll, revealed she experienced suicidal thoughts while taking semaglutide, describing December 2025 as "one of the darkest times of my life." She emphasized the importance of discussing mental health side effects of weight-loss medications and encouraged others facing similar struggles to seek help.
Novo Nordisk announced it will reduce the list price of its semaglutide products Ozempic, Wegovy and Rybelsus to $675 starting January 1, 2027, representing cuts of up to 50 percent from current pricing.
Microdosing GLP-1 medications like Ozempic and Wegovy has emerged as a weight-loss trend, but health experts warn there is no scientific data supporting the practice and caution about potential safety risks.
Multiple television personalities have openly discussed their use of GLP-1 medications for weight loss, with some experiencing facial changes known as "Ozempic face" characterized by volume loss and more pronounced features.
